Literature DB >> 15220024

Productivity costs and determinants of productivity in HIV-infected patients.

Pedram Sendi1, Fabian Schellenberg, Chaiwat Ungsedhapand, Gilbert R Kaufmann, Heiner C Bucher, Rainer Weber, Manuel Battegay.   

Abstract

BACKGROUND: In HIV-infected patients, reduced ability to work may be an important component of the societal costs of this disease. Few data about productivity costs in HIV-infected patients are available.
OBJECTIVE: The goals of this study were to estimate productivity costs in the HIV-infected population in Switzerland and to identify characteristics that may influence patient productivity.
METHODS: This cross-sectional study included all patients younger than retirement age (65 years for men and 62 years for women) who were enrolled in the Swiss HIV Cohort Study in 2002. Measures of productivity losses in this population were based on patients' ability to work and the median monthly wage rates adjusted for age, sex, and educational level in Switzerland. Factors associated with ability to work were analyzed in a multivariate ordinary logistic regression (proportional odds) model. As of July 1, 2002, the exchange rate for US dollars to Swiss francs (CHF) was US $1.00 approximately equal to CHF 1.48.
RESULTS: A total of 5319 HIV-infected patients (3665 men [68.9%] and 1655 women [31.1%]; mean [SD] age, 40.6 [8.4] years; range, 17-64 years) were included in the study. The mean annual productivity loss per patient was estimated at CHF 22,910 (95% CI, CHF 22,064-CHF 23, 756). Ability to work was independently associated with the following (P < 0.001 for all): age (10-year increase: odds ratio [OR], 0.60 [95% CI, 0.54-0.62]), sex (female/male: OR, 0.73 [95% CI, 0.63-0.84]), history of IV drug use (OR, 0.22 [95% CI, 0.19-0.26]), time since first positive HIV test (>10 years vs < or = 10 years: OR, 0.66 [95% CI, 0.58-0.76]), CD4 cell count (201-500 vs 0-200 cells/microL: OR, 1.68 [95% CI, 1.38-2.46]; > or =501 vs 0-200 cells/microL: OR, 2.01 [95%, CI, 1.64-2.46]), history of AIDS-indicator disease (OR, 0.47 [95% CI, 0.41-0.55]), stable partnership during the last 6 months (OR, 1.63 [95% CI, 1.43-1.86]), and educational level (higher vs basic: OR, 1.68 [95% CI, 1.45-1.95]).
CONCLUSIONS: Productivity losses to society for the HIV-infected population appeared to be substantial in this analysis. Given a patient's clinical health status, a higher education level and a stable partnership were associated with greater ability to work. Socioeconomic characteristics may influence the cost-effectiveness of health care interventions in HIV-infected patients.

Entities:  

Mesh:

Year:  2004        PMID: 15220024     DOI: 10.1016/s0149-2918(04)90080-x

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  11 in total

1.  US cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial.

Authors:  Anita Brogan; Josephine Mauskopf; Sandra E Talbird; Erik Smets
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

2.  Cost effectiveness of darunavir/ritonavir in highly treatment-experienced, HIV-1-infected adults in the USA.

Authors:  Josephine Mauskopf; Anita Brogan; Silas Martin; Erik Smets
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

3.  [Morbidity and mortality in HIV infection].

Authors:  M Stöckle; L Elzi; J K Rockstroh; M Battegay
Journal:  Internist (Berl)       Date:  2012-10       Impact factor: 0.743

4.  The effect of HIV infection on time off work in a large cohort of gold miners with known dates of seroconversion.

Authors:  Pam Sonnenberg; Andrew Copas; Judith R Glynn; Andre Bester; Gill Nelson; Stuart Shearer; Jill Murray
Journal:  Occup Environ Med       Date:  2010-11-28       Impact factor: 4.402

5.  Cost-effectiveness of genotypic antiretroviral resistance testing in HIV-infected patients with treatment failure.

Authors:  Pedram Sendi; Huldrych F Günthard; Mathew Simcock; Bruno Ledergerber; Jörg Schüpbach; Manuel Battegay
Journal:  PLoS One       Date:  2007-01-24       Impact factor: 3.240

6.  Cost-Effectiveness of Dolutegravir in HIV-1 Treatment-Naive and Treatment-Experienced Patients in Canada.

Authors:  Nicolas Despiégel; Delphine Anger; Monique Martin; Neerav Monga; Qu Cui; Angela Rocchi; Sonia Pulgar; Kim Gilchrist; Rodrigo Refoios Camejo
Journal:  Infect Dis Ther       Date:  2015-06-23

7.  The economic burden of HIV/AIDS on individuals and households in Nepal: a quantitative study.

Authors:  Ak Narayan Poudel; David Newlands; Padam Simkhada
Journal:  BMC Health Serv Res       Date:  2017-01-24       Impact factor: 2.655

8.  The economic costs and health-related quality of life of people with HIV/AIDS in the Canary Islands, Spain.

Authors:  Julio Lopez-Bastida; Juan Oliva-Moreno; Lilisbeth Perestelo-Perez; Pedro Serrano-Aguilar
Journal:  BMC Health Serv Res       Date:  2009-03-30       Impact factor: 2.655

9.  Cost of hospital care for HIV/AIDS infected patients in three general reference hospitals in Lubumbashi, DR Congo: prospective cohort study.

Authors:  Henri Mundongo Tshamba; Clarence Mukeng a Kaut; Nono Mulubwa Kyalubile; Alphonse Kaij Kakambal; Grevisse Ditend Yav; Françoise Malonga Kaj; Didier Vancaillie
Journal:  Pan Afr Med J       Date:  2013-06-26

10.  Ability to Work and Employment Rates in Human Immunodeficiency Virus (HIV)-1-Infected Individuals Receiving Combination Antiretroviral Therapy: The Swiss HIV Cohort Study.

Authors:  Luigia Elzi; Anna Conen; Annalea Patzen; Jan Fehr; Matthias Cavassini; Alexandra Calmy; Patrick Schmid; Enos Bernasconi; Hansjakob Furrer; Manuel Battegay
Journal:  Open Forum Infect Dis       Date:  2016-02-01       Impact factor: 3.835

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.